Therapy for Atopic Dermatitis, Contact Dermatitis and Chronic Urticaria: Recent Advances

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".

Deadline for manuscript submissions: closed (17 November 2023) | Viewed by 423

Special Issue Editors


E-Mail Website
Guest Editor
Dermatology Department, University Hospital Virgen de las Nieves, 18014 Granada, Spain
Interests: atopic dermatitis; barrier function; contact dermatitis; personalized medicine; predictive medicine; urticaria
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Atopic dermatitis, contact dermatitis and chronic urticaria are frequent skin diseases with a great impact on the patient’s quality of life. Many treatments have been used for treating these diseases for years with low or moderate results and with many undesirable side effects. Recently, several new molecules have been introduced with promising results. The introduction of interleukin inhibitors, including dupilumab, tralokinumab and lebrikizumab, and Janus kinase inhibitors, such as baricitinib, upadacitinib and abrocitinib, have changed the paradigm of atopic dermatitis. Moreover, other targets involved in the pathogenesis of this disease are being investigated (IL-31, OX40 or IL36). The mainstay of treatment of contact dermatitis is avoidance of the allergen, but it is sometimes needed to use systemic drugs. The emergence of omalizumab, an anti Ig-E antibody, has improved clinical outcomes of chronic urticaria. Moreover, further developments, including novel biologics, novel oral therapies, and gene therapy approaches, are being developed to broaden therapeutic options for patients with chronic urticaria and hereditary angioedema. Thus, the objective of this Special Issue is to provide information about advances in the treatment of atopic dermatitis, contact dermatitis and chronic urticaria.

Dr. Trinidad Montero-Vilchez
Prof. Dr. Salvador Arias-Santiago
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • atopic dermatitis
  • biological products
  • chronic urticaria
  • contact dermatitis
  • Janus Kinase inhibitors
  • monoclonal antibodies
  • skin
  • therapeutics

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop